Dr. David Henderson
Senior Biologist at Mironid
David Henderson is responsible for the efficient and effective delivery of lab based and collaborative research programs covering novel compound development, biomarker discovery and target validation. Prior to taking up this position with Mironid, David won a prestigious Innovation Fellowship at the Salk Institute for biological studies, San Diego, for his work in epigenetic dysregulation in precancerous disease. David’s previous work on cAMP signaling in prostate cancer laid the groundwork for the development of a new prognostic biomarker by MDX Health (InformDXTM). This new biomarker test has now been shown to aid in the meaningful therapeutic risk stratification of prostate cancer patients.
Mironid Ltd is an innovative drug discovery company focused on delivering new best-in-class therapeutics for kidney disease, inflammation and cancer.
Title: The discovery and description PDE4D7 as a new prognostic biomarker for advancing prostate cancer
- The rationale behind the project and the project timelines
- A description of it the initial characterization of the biomarker, and subsequent validation and follow-up studies
- Its current status: anticipated launch by MDxHealth as ‘InformMDxTM’ in 2019